topic

Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer
Kenji Fujiwara, May Tun Saung, Hao Jing, Brian Herbst, MacKenzie Zarecki, Stephen Muth, Annie Wu, Elaine Bigelow, Linda Chen, Keyu Li, Neolle Jurcak, Alex B Blair, Ding Ding, Michael Wichroski, Jordan Blum, Nathan Cheadle, Jennifer Koenitzer, Lei Zheng

Journal for ImmunoTherapy of Cancer Jul 2020, 8 (2) e000351; DOI: 10.1136/jitc-2019-000351
Local injection of CCL19-expressing mesenchymal stem cells augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration of immune cells
Yuichi Iida, Rintaro Yoshikawa, Akihiko Murata, Hitoshi Kotani, Yasuhiro Kazuki, Mitsuo Oshimura, Yumi Matsuzaki, Mamoru Harada

Journal for ImmunoTherapy of Cancer Jul 2020, 8 (2) e000582; DOI: 10.1136/jitc-2020-000582
Correction: Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis
Journal for ImmunoTherapy of Cancer Jul 2020, 8 (2) e0779-6corr1; DOI: 10.1136/jitc-2020-0779-6corr1
Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy
Christopher A Chuckran, Chang Liu, Tullia C Bruno, Creg J Workman, Dario AA Vignali

Journal for ImmunoTherapy of Cancer Jul 2020, 8 (2) e000967; DOI: 10.1136/jitc-2020-000967
Immunization associated with primary tumor growth leads to rejection of commonly used syngeneic tumors upon tumor rechallenge
Bruno Alicke, Klara Totpal, Jill M Schartner, Amy M Berkley, Sophie M Lehar, Aude-Hélène Capietto, Rafael A Cubas, Stephen E Gould

Journal for ImmunoTherapy of Cancer Jul 2020, 8 (2) e000532; DOI: 10.1136/jitc-2020-000532
ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19
Riyue Bao, Kyle Hernandez, Lei Huang, Jason John Luke

Journal for ImmunoTherapy of Cancer Jul 2020, 8 (2) e001020; DOI: 10.1136/jitc-2020-001020
Hematopoietic lineage-converted T cells carrying tumor-associated antigen-recognizing TCRs effectively kill tumor cells
Fangxiao Hu, Dehao Huang, Yuxuan Luo, Peiqing Zhou, Cui Lv, Kaitao Wang, Qitong Weng, Xiaofei Liu, Yuxian Guan, Yang Geng, Juan Du, Jiekai Chen, Jinyong Wang, Hongling Wu

Journal for ImmunoTherapy of Cancer Jul 2020, 8 (2) e000498; DOI: 10.1136/jitc-2019-000498
Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective
Casey Quinn, Louis P Garrison, Anja K Pownell, Michael B Atkins, Gérard de Pouvourville, Kevin Harrington, Paolo Antonio Ascierto, Phil McEwan, Samuel Wagner, John Borrill, Elise Wu

Journal for ImmunoTherapy of Cancer Jul 2020, 8 (2) e000648; DOI: 10.1136/jitc-2020-000648
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
Nina Shah, Jack Aiello, David E Avigan, Jesus G Berdeja, Ivan M Borrello, Ajai Chari, Adam D Cohen, Karthik Ganapathi, Lissa Gray, Damian Green, Amrita Krishnan, Yi Lin, Elisabet Manasanch, Nikhil C Munshi, Ajay K Nooka, Aaron P Rapoport, Eric L Smith, Ravi Vij, Madhav Dhodapkar

Journal for ImmunoTherapy of Cancer Jul 2020, 8 (2) e000734; DOI: 10.1136/jitc-2020-000734
Correction: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Journal for ImmunoTherapy of Cancer Jul 2020, 8 (2) e000391corr1; DOI: 10.1136/jitc-2019-000391corr1

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages